KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Operating Expenses: 2015-2025

Historic Operating Expenses for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $1.1 billion.

  • BeOne Medicines' Operating Expenses rose 10.64% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 12.42%. This contributed to the annual value of $3.8 billion for FY2024, which is 15.15% up from last year.
  • Latest data reveals that BeOne Medicines reported Operating Expenses of $1.1 billion as of Q3 2025, which was down 0.95% from $1.1 billion recorded in Q2 2025.
  • BeOne Medicines' 5-year Operating Expenses high stood at $1.1 billion for Q2 2025, and its period low was -$1.2 billion during Q4 2021.
  • For the 3-year period, BeOne Medicines' Operating Expenses averaged around $920.7 million, with its median value being $912.4 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 297.07% in 2021, then spiked by 148.77% in 2022.
  • Over the past 5 years, BeOne Medicines' Operating Expenses (Quarterly) stood at -$1.2 billion in 2021, then skyrocketed by 148.77% to $562.2 million in 2022, then surged by 62.27% to $912.4 million in 2023, then rose by 14.72% to $1.0 billion in 2024, then increased by 10.64% to $1.1 billion in 2025.
  • Its Operating Expenses stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $941.2 million for Q1 2025.